Minerva Neurosciences (NERV) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Minerva Neurosciences (NERV) has outperformed PepGen (PEPG) over the past year, gaining 50.0% versus a loss of 51.1%. PepGen is the larger company by market cap ($166.0 million vs $156.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NERV | PEPG |
|---|---|---|
| Share price | $3.27 | $2.40 |
| Market cap | $156.13M | $166.01M |
| 1-day change | -4.66% | +3.90% |
| YTD return | -18.66% | -63.13% |
| 1-year return | +50.00% | -51.12% |
| 5-year return | -69.72% | — |
| EPS (TTM) | $-34.49 | $-1.05 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.46 | $7.80 |
| 52-week low | $2.24 | $1.31 |
| Distance from 52-week high | -73.76% | -69.23% |
| Analyst consensus | none | none |
| Avg. price target upside | +215.90% | +324.58% |
| Average volume | 185.68K | 976.87K |
| Shares outstanding | 47.75M | 69.17M |
| Employees | 7 | 57 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NERV has outperformed PEPG by 101.1 percentage points over the past year.
About Minerva Neurosciences
NERV stock →Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
Healthcare · Biotechnology · 7 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Healthcare · Biotechnology · 57 employees
NERV vs PEPG FAQ
Which is bigger, Minerva Neurosciences or PepGen?
PepGen (PEPG) is larger, with a market capitalization of $166.01M compared with $156.13M for Minerva Neurosciences (NERV).
Which stock has performed better over the past year, NERV or PEPG?
NERV returned +50.00% over the past 12 months, compared with -51.12% for PEPG (price return, excluding dividends). Past performance does not predict future results.
Are Minerva Neurosciences and PepGen in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.